Heat shock protein 90 (Hsp90) is a molecular chaperone that is responsible for the folding and maturation of client proteins that are associated with all ten hallmarks of cancer. Hsp90 N-terminal pan inhibitors have experienced unfavorable results in clinical trials due to induction of the heat shock response (HSR), among other concerns. Novobiocin, a well characterized DNA gyrase B inhibitor, was identified as the first Hsp90 C-terminal inhibitor that manifested anticancer effects without induction of the HSR. In this letter, a library of Hsp90 C-terminal inhibitors derived from a benzothiazole-based scaffold, known to inhibit DNA gyrase B, was designed, synthesized, and evaluated. Several compounds were found to manifest low micromolar activity against both MCF-7 and SKBr3 breast cancer cell lines via Hsp90 C-terminal inhibition.

中文翻译：

---

从细菌到癌症：一种基于苯并噻唑的 DNA 促旋酶 B 抑制剂重新设计用于 Hsp90 C 端抑制。

热休克蛋白 90 (Hsp90) 是一种分子伴侣，负责与癌症的所有十个标志相关的客户蛋白的折叠和成熟。由于热休克反应 (HSR) 的诱导以及其他问题，Hsp90 N 端泛抑制剂在临床试验中经历了不利的结果。Novobiocin 是一种充分表征的 DNA 促旋酶 B 抑制剂，被鉴定为第一个 Hsp90 C 末端抑制剂，它在不诱导 HSR 的情况下表现出抗癌作用。在这封信中，设计、合成和评估了一个源自苯并噻唑支架的 Hsp90 C 端抑制剂库，已知可抑制 DNA 促旋酶 B。发现几种化合物通过 Hsp90 C 末端抑制对 MCF-7 和 SKBr3 乳腺癌细胞系表现出低微摩尔活性。